Laurus Labs Careers logo

Laurus Labs Careers

An India-based pharmaceutical development and manufacturing company.

lauruslabs.com

About the company

Legal name

Laurus Labs Limited

Founded

2005

Industry

Pharmaceutical development and manufacturing

Revenue (FY26)

₹6,813 crore

EBITDA (FY26)

₹1,826 crore

EBITDA margin (FY26)

26.8%

Employees

8,126 (as of 31 March 2026)

Manufacturing sites

15

R&D sites

6

Listed on

NSE: LAURUSLABS / BSE: 540222

CIN

L24239AP2005PLC047518

CEO

Dr. Satyanarayana Chava

Laurus Labs Limited is a research-driven pharmaceutical and biotechnology company founded in 2005 by Dr. Satyanarayana Chava, who remains its Founder and Chief Executive Officer. Its corporate office is in Jubilee Hills, Hyderabad, and its registered office is at Laurus Enclave in Parawada mandal, Anakapalli district, Andhra Pradesh. The shares trade on the NSE as LAURUSLABS and on the BSE under 540222. The company holds a leading position in active pharmaceutical ingredients and finished dosage forms for anti-retroviral, oncology, cardiovascular and gastro therapeutics.

Laurus reports two divisions. CDMO serves innovator companies from early development through commercial supply, covering small molecules and, through Laurus Bio, large molecules and enzymes. Affordable Medicines covers generic APIs and finished dosage forms, with anti-retrovirals still a large share. In the first half of FY27, CDMO revenue rose 71% to ₹1,774 crore and Affordable Medicines grew 13% to ₹2,459 crore, taking total revenue to ₹4,233 crore at a 33.2% EBITDA margin. The group also supplies animal-health APIs, intermediates, crop-science and specialty ingredients for nutrition and cosmetics, and it has invested in cell and gene therapy through a minority stake in ImmunoACT.

The company set up its R&D operation in 2006 and its first plant, Unit 1 at Visakhapatnam, in 2007. It filed its first Drug Master File and supplied its first product to the US in 2008. Unit 1 won USFDA, TGA and UK MHRA approval in 2010, and the first finished-dosage product, Tenofovir, launched in the US, Canada and emerging markets in 2018. Later steps include buying Aspen's South African subsidiary in 2020, taking 72.55% of Richcore Life Sciences (now Laurus Bio) in 2021, a joint venture with KRKA in January 2024 and a new R&D centre at IKP Knowledge Park, Genome Valley, opened in September 2024. In October 2026 Laurus agreed to take 60% of Galenvs Sciences, a Montréal oligonucleotide and magnetic-nanoparticle specialist.

Manufacturing runs across 15 sites approved by regulators including the USFDA, WHO and EMA, including facilities near Visakhapatnam at Parawada and the APSEZ at Atchutapuram. The FY26 annual report lists 8,200 KL of reactor volume, 12 billion units of formulation capacity and 240 KL of fermentation capacity. In 2026 the company opened its first commercial-scale peptide plant in Vizag with more than 16,000 litres of solid-phase peptide synthesis capacity, and its LB-4 fermentation unit of over 400 kL is due to be commissioned in the third quarter of FY27. Six R&D sites spent ₹282 crore in FY26. Laurus has filed 600+ patents and 92 DMFs, has 96 finished-dosage products filed in developed markets and runs 125+ active CDMO projects.

Headcount reached 8,126 on 31 March 2026, up from 7,042 a year earlier, after more than 1,700 hires. About 3,134 of these employees are scientists and quality staff. Attrition fell to 10.3% from 17%, and millennials make up 88% of the permanent workforce. Women were 9% of employees in FY26, and the company ran walk-in drives in Goa, Hyderabad, Ahmedabad and Chennai alongside campus hiring. Its 2025 DARPAN engagement survey reached 6,553 employees with a 96% response rate and a Trust Index of 83, and Laurus has been certified a Great Place to Work for six consecutive years.

Key People

Dr. Satyanarayana Chava

Executive Director and Chief Executive Officer

Mr. V. V. Ravi Kumar

Executive Director and Chief Financial Officer

Dr. Lakshmana Rao C V

Executive Director, Quality

Mr. Krishna Chaitanya Chava

Executive Director, CDMO Small Molecules

Photos

Laurus Labs workplace 1

Interview process at Laurus Labs

Interview experience

No numeric score verified

Interview difficulty

No numeric score verified

Interview process length

Varies by role

See all Laurus Labs interview questions & answers

Browse question banks by role, round and company, with answers and examples.

Benefits

Learning opportunities
Technology and policy learning
Structured induction, Laurus Ignite sessions and a SANCHALAK mentor for new joiners
MANTHAN management development programme for middle managers, with 360-degree reviews
Gearing Up Leaders for Tomorrow (GUT) programme for succession readiness
PIONEER and SYNERGY programmes for Level 2-4 and Level 5-7 employees
Elantree leadership and Prabuddha emotional-intelligence programmes
Laurus Learning portal and mobile app
Employee Assistance Programme with confidential counselling for employees and family
Monthly mental-wellness and personal-development workshops
Dietitian-reviewed meals from in-house kitchens
Gyms with trainers and shuttle courts at plant locations
Childcare support and engagement initiatives for women employees
Family Day, children's summer camps and Sports Week
Employee stock options (Laurus ESOP) for eligible employees
Laurus Employee Trust support during financial emergencies
Retention bonus framework for select employee categories
Long-service cash awards at 10 and 15 years
Residential support for designated employees and their families

Latest News & Updates

October 29, 2026

Laurus Labs takes majority stake in Galenvs Sciences

Laurus signed an agreement to acquire 60% of Galenvs Sciences, a Montréal biotechnology company working on oligonucleotides and precision magnetic nanoparticles. The company said the deal strengthens its TIDES and CDMO capabilities, with scientific talent growing in Montréal and manufacturing in India.

#Acquisition #CDMO #Biotech

View post

October 29, 2026

Laurus Labs announces H1 FY27 results

First-half revenue rose 31% to ₹4,233 crore and EBITDA rose 72% to ₹1,406 crore, a 33.2% margin. CDMO small-molecule revenue grew 77%, the company opened its first commercial-scale peptide plant in Vizag, and it declared an interim dividend of ₹1 per share.

#Results #Pharma

View post

July 24, 2026

Laurus Labs announces Q1 FY27 results

The company reported first-quarter revenue of ₹2,026 crore and EBITDA of ₹644 crore, a 31.8% margin.

#Results #Investor

View post

May 21, 2026

Laurus Labs included in Dow Jones Best-in-Class indices

The company listed its inclusion in the Dow Jones Best-in-Class indices in its regulatory disclosures.

#Sustainability #Recognition

View post

April 30, 2026

Laurus Labs announces full-year FY26 results

The company reported FY26 revenue of ₹6,813 crore and EBITDA of ₹1,826 crore.

#Results #Pharma

View post

Laurus Labs FAQ

Its corporate office is in Jubilee Hills, Hyderabad, Telangana. The registered office is at Laurus Enclave in Anakapalli district, Andhra Pradesh, near the company's main manufacturing base around Visakhapatnam.

Last updated: